4 results match your criteria: "2401 Centre[Affiliation]"
Biometals
October 2012
Department of VA, Veterans Health Administration, Office of Research and Development, VA Cooperative Studies Program Clinical Research Pharmacy Coordinating Center, 2401 Centre Avenue SE, Albuquerque, NM 87106, USA.
Reticuloendothelial blockade in hemodialysis patients prevents optimal intravenous (IV) iron utilization. Vitamin C has emerged as a potential therapy to improve anemia treatment by enhancing iron mobilization. However, Vitamin C can act as a pro-oxidant in the presence of iron.
View Article and Find Full Text PDFClin Trials
January 2014
VA Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, 2401 Centre Ave. SE, Albuquerque, NM 87106, USA.
Background: Assessment of adherence to study medications is a common challenge in clinical research. Counting unused study medication is the predominant method by which adherence is assessed in outpatient clinical trials but it has limitations that include questionable validity and burdens on research personnel.
Purpose: To compare capsule counts, patient questionnaire responses, and plasma drug levels as methods of determining adherence in a clinical trial that had 2056 participants and used centralized drug distribution and patient follow-up.
J Am Pharm Assoc (2003)
April 2006
Biopharmaceutics/Pharmacokinetics Laboratory, VA Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, 2401 Centre Ave., SE, Albuquerque, NM 87106, USA.
Objective: To select a high-quality chondroitin dosage form and/or an appropriate source of sodium chondroitin for the National Institutes of Health's Glucosamine/Chondroitin Arthritis Intervention Trial (GAIT).
Design: Controlled experimental trials.
Setting: Laboratory.
Ann Pharmacother
February 2002
Veterans Affairs Cooperative Studies Program, Clinical Research Pharmacy Coordinating Center, 2401 Centre, SE, Albuquerque, NM 87106-4180, USA.
Objective: To review opioid dependence (OD) and its treatment. Pharmacologic treatments, including the use of buprenorphine/naloxone, are presented. Pharmaceutical care functions for outpatient OD treatment are discussed.
View Article and Find Full Text PDF